Combined	0	8	O
topical	9	16	O
fluconazole	17	28	B-Drug_or_compound
and	29	32	O
corticosteroid	33	47	B-Drug_or_compound
treatment	48	57	O
for	58	61	O
experimental	62	74	O
Candida	75	82	B-Organism
albicans	83	91	I-Organism
keratomycosis	92	105	O
.	105	106	O

PURPOSE	108	115	O
:	115	116	O
To	117	119	O
determine	120	129	O
the	130	133	O
most	134	138	O
efficient	139	148	O
time	149	153	O
point	154	159	O
and	160	163	O
concentration	164	177	O
of	178	180	O
topical	181	188	O
corticosteroids	189	204	B-Drug_or_compound
in	205	207	O
Candida	208	215	B-Organism
albicans	216	224	I-Organism
keratitis	225	234	O
treated	235	242	O
with	243	247	O
fluconazole	248	259	B-Drug_or_compound
.	259	260	O

METHODS	261	268	O
:	268	269	O
Corneas	270	277	B-Multi-tissue_structure
of	278	280	O
105	281	284	O
rabbits	285	292	B-Organism
were	293	297	O
infected	298	306	O
with	307	311	O
viable	312	318	O
yeast	319	324	B-Organism
cells	325	330	B-Cell
of	331	333	O
C	334	335	B-Organism
.	335	336	I-Organism
albicans	337	345	I-Organism
(	346	347	O
2	347	348	O
.	348	349	O
5	349	350	O
x	351	352	O
10	353	355	O
(	355	356	O
5	356	357	O
)	357	358	O
)	358	359	O
.	359	360	O

After	361	366	O
a	367	368	O
48	369	371	O
-	371	372	O
hour	372	376	O
incubation	377	387	O
period	388	394	O
,	394	395	O
seven	396	401	O
groups	402	408	O
of	409	411	O
animals	412	419	O
were	420	424	O
treated	425	432	O
for	433	436	O
21	437	439	O
days	440	444	O
with	445	449	O
fluconazole	450	461	B-Drug_or_compound
,	461	462	O
with	463	467	O
group	468	473	O
I	474	475	O
acting	476	482	O
as	483	485	O
a	486	487	O
control	488	495	O
,	495	496	O
and	497	500	O
groups	501	507	O
II	508	510	O
to	511	513	O
VII	514	517	O
receiving	518	527	O
adjunct	528	535	O
therapy	536	543	O
with	544	548	O
the	549	552	O
corticosteroid	553	567	B-Drug_or_compound
prednisolone	568	580	B-Drug_or_compound
(	581	582	O
5	582	583	O
or	584	586	O
10	587	589	O
times	590	595	O
daily	596	601	O
;	601	602	O
3	603	604	O
,	604	605	O
9	606	607	O
,	607	608	O
or	609	611	O
15	612	614	O
days	615	619	O
after	620	625	O
infection	626	635	O
)	635	636	O
.	636	637	O

The	638	641	O
degree	642	648	O
of	649	651	O
corneal	652	659	B-Multi-tissue_structure
infiltration	660	672	O
,	672	673	O
ulceration	674	684	O
,	684	685	O
corneal	686	693	B-Multi-tissue_structure
clouding	694	702	O
,	702	703	O
hypopyon	704	712	O
,	712	713	O
conjunctivitis	714	728	O
,	728	729	O
neovascularization	730	748	O
,	748	749	O
and	750	753	O
corneal	754	761	B-Multi-tissue_structure
perforation	762	773	O
was	774	777	O
monitored	778	787	O
over	788	792	O
a	793	794	O
24	795	797	O
-	797	798	O
day	798	801	O
period	802	808	O
,	808	809	O
as	810	812	O
well	813	817	O
as	818	820	O
recultivation	821	834	O
and	835	838	O
resistance	839	849	O
to	850	852	O
fluconazole	853	864	B-Drug_or_compound
of	865	867	O
the	868	871	O
C	872	873	B-Organism
.	873	874	I-Organism
albicans	875	883	I-Organism
pathogen	884	892	O
.	892	893	O

RESULTS	894	901	O
:	901	902	O
The	903	906	O
control	907	914	O
group	915	920	O
showed	921	927	O
the	928	931	O
highest	932	939	O
level	940	945	O
of	946	948	O
corneal	949	956	B-Multi-tissue_structure
clouding	957	965	O
and	966	969	O
neovascularization	970	988	O
.	988	989	O

In	990	992	O
comparison	993	1003	O
,	1003	1004	O
by	1005	1007	O
day	1008	1011	O
24	1012	1014	O
,	1014	1015	O
the	1016	1019	O
majority	1020	1028	O
of	1029	1031	O
groups	1032	1038	O
also	1039	1043	O
treated	1044	1051	O
with	1052	1056	O
prednisolone	1057	1069	B-Drug_or_compound
displayed	1070	1079	O
significantly	1080	1093	O
less	1094	1098	O
corneal	1099	1106	B-Multi-tissue_structure
clouding	1107	1115	O
and	1116	1119	O
neovascularization	1120	1138	O
.	1138	1139	O

An	1140	1142	O
immediate	1143	1152	O
decrease	1153	1161	O
in	1162	1164	O
corneal	1165	1172	B-Multi-tissue_structure
clouding	1173	1181	O
was	1182	1185	O
observed	1186	1194	O
in	1195	1197	O
groups	1198	1204	O
treated	1205	1212	O
with	1213	1217	O
additional	1218	1228	O
low	1229	1232	O
-	1232	1233	O
or	1234	1236	O
high	1237	1241	O
-	1241	1242	O
dose	1242	1246	O
prednisolone	1247	1259	B-Drug_or_compound
from	1260	1264	O
day	1265	1268	O
9	1269	1270	O
after	1271	1276	O
inoculation	1277	1288	O
.	1288	1289	O

After	1290	1295	O
additional	1296	1306	O
prednisolone	1307	1319	B-Drug_or_compound
treatment	1320	1329	O
from	1330	1334	O
day	1335	1338	O
9	1339	1340	O
or	1341	1343	O
15	1344	1346	O
after	1347	1352	O
inoculation	1353	1364	O
,	1364	1365	O
no	1366	1368	O
significant	1369	1380	O
difference	1381	1391	O
was	1392	1395	O
detected	1396	1404	O
in	1405	1407	O
the	1408	1411	O
recultivation	1412	1425	O
rate	1426	1430	O
of	1431	1433	O
C	1434	1435	B-Organism
.	1435	1436	I-Organism
albicans	1437	1445	I-Organism
compared	1446	1454	O
with	1455	1459	O
the	1460	1463	O
control	1464	1471	O
.	1471	1472	O

Early	1473	1478	O
administration	1479	1493	O
of	1494	1496	O
prednisolone	1497	1509	B-Drug_or_compound
(	1510	1511	O
day	1511	1514	O
3	1515	1516	O
,	1516	1517	O
low	1518	1521	O
and	1522	1525	O
high	1526	1530	O
dose	1531	1535	O
)	1535	1536	O
resulted	1537	1545	O
in	1546	1548	O
the	1549	1552	O
recultivation	1553	1566	O
of	1567	1569	O
significantly	1570	1583	O
more	1584	1588	O
C	1589	1590	B-Organism
.	1590	1591	I-Organism
albicans	1592	1600	I-Organism
.	1600	1601	O

CONCLUSIONS	1602	1613	O
:	1613	1614	O
Fluconazole	1615	1626	B-Drug_or_compound
plus	1627	1631	O
adjunct	1632	1639	O
high	1640	1644	O
-	1644	1645	O
dose	1645	1649	O
prednisolone	1650	1662	B-Drug_or_compound
treatment	1663	1672	O
was	1673	1676	O
most	1677	1681	O
effective	1682	1691	O
when	1692	1696	O
administered	1697	1709	O
9	1710	1711	O
days	1712	1716	O
after	1717	1722	O
infection	1723	1732	O
.	1732	1733	O

The	1734	1737	O
delayed	1738	1745	O
application	1746	1757	O
of	1758	1760	O
corticosteroids	1761	1776	B-Drug_or_compound
after	1777	1782	O
treatment	1783	1792	O
with	1793	1797	O
antimycotic	1798	1809	B-Drug_or_compound
drugs	1810	1815	I-Drug_or_compound
in	1816	1818	O
cases	1819	1824	O
of	1825	1827	O
fungal	1828	1834	O
keratitis	1835	1844	O
is	1845	1847	O
therefore	1848	1857	O
not	1858	1861	O
contraindicated	1862	1877	O
and	1878	1881	O
may	1882	1885	O
be	1886	1888	O
beneficial	1889	1899	O
in	1900	1902	O
patients	1903	1911	B-Organism
.	1911	1912	O

